MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC
Position in APLS — Apellis Pharmaceuticals, Inc.
CIK 922127
New York, NY
Position in APLS
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$0
+$0 QoQ
Shares Held
11,728
-56.9% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2022
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in APLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC holds $184,059,662 across 45 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
191,432 | $15,603,622 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
26,109 | $12,969,123 | |
| 3 | KRYS |
Krystal Biotech, Inc.
|
31,998 | $11,892,696 | |
| 4 | CYTK |
Cytokinetics Inc
|
121,652 | $10,363,533 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
40,364 | $9,879,896 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
12,418 | $6,667,845 | |
| 7 | XENE |
Xenon Pharmaceuticals Inc.
|
109,603 | $6,615,637 | |
| 8 | VCEL |
Vericel Corp
|
145,445 | $6,470,848 |
All Filings in APLS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 11,728 | Shares | Sole | 2026-05-07 | |
| 2024-09-30 | — | 27,211 | Shares | Sole | 2024-11-06 | |
| 2024-06-30 | — | 27,466 | Shares | Sole | 2024-08-09 | |
| 2024-03-31 | — | 28,654 | Shares | Sole | 2024-05-02 | |
| 2023-12-31 | — | 30,982 | Shares | Sole | 2024-01-26 | |
| 2023-09-30 | — | 41,514 | Shares | Sole | 2023-11-09 | |
| 2023-06-30 | — | 43,984 | Shares | Sole | 2023-08-11 | |
| 2023-03-31 | — | 26,852 | Shares | Sole | 2023-05-04 | |
| 2022-12-31 | — | 28,089 | Shares | Sole | 2023-02-10 | |
| 2022-09-30 | — | 27,711 | Shares | Sole | 2022-11-08 | |
| No filing history on record for this holder in this stock. | ||||||